We are monitoring the impact of COVID-19 on MEA Antiviral Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1513
Share on
Share on

Middle East & Africa Antiviral Drugs Market Research Report - Segmented By Application , By Target, By End Users & By Country(KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA)- Industry Analysis, Size, Share, Growth, Trends, And Forecasts | 2019-2024

Pulished: February, 2020
ID: 1513
Pages: 142

MEA Antiviral Drugs Market Size & Growth (2019 - 2024)

As per the research report, the size of the Middle East & Africa Antiviral Drugs Market is valued at USD 2.25 billion in 2019 and is expected to reach USD 2.89 billion by 2024, growing at a CAGR of 5.07% during the forecast period 2019-2024.

Antiviral Drugs helps in combating viral infections by hampering the replication of viruses and strengthening the immune response to the viral infection. From the past few years resistance is observed among viruses against different antiviral drugs with increasing diversity of viruses. This challenge leads to the evolution of broad spectrum antiviral drugs that specifically attack viruses at specified targets such as DNA Polymerase, NS3 Protease, & Reverse Transcriptase. These drugs are used to prevent or cure different viral infections such as HIV/AIDS, Hepatitis, influenza, and other viral infections.

The growth of Antiviral Drugs in Middle East & Africa market is majorly driven by factors such as increased public awareness, rise in healthcare expenditure, emergence of life-threatening diseases, and increase in viral infection incidences. The key restraints of the market are high cost involved in drug development, lack of incentivization, use of natural medicines, and limited access to healthcare. The countries with average and low level income such as Africa are highly susceptible to acute and chronic diseases like influenza, HIV/AIDS, and hepatitis due to lack of basic healthcare facilities, high cost of life-saving drugs, and import restriction. Lack of public awareness about chronic and transmissible diseases also makes the region extremely vulnerable. As per World Health Organization, 25.6 million people are living with HIV in Sub-Saharan Africa in 2015, making it one of the most affected region, but high pricing keep the product out of the reach of most people.

This research report segmented and sub-segmented into the following categories:

  • By Application: HIV/AIDS, Hepatitis, Herpes, Influenza, And Others
  • By Target: DNA Polymerase, NS3 Protease, Reverse Transcriptase, And Others
  • By End Users: Hospitals, Research Institutes, And Laboratory Centers
  • By Country: KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA

The leading companies leading in the MEA Antiviral Drugs Market profiled in the report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Roche Holding AG (Switzerland), Pfizer (USA), Merck and Co. Inc (USA), GlaxoSmithKline plc (United Kingdom), AstraZeneca AB (United Kingdom), Gilead Sciences (USA), and Abbott Laboratories (USA).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Application                 

                                5.1.1 Introduction           

                                5.1.2 HIV/AIDS

                                5.1.3 Hepatitis  

                                5.1.4 Herpes     

                                5.1.5 Influenza 

                                5.1.6 Others      

                                5.1.7 Y-o-Y Growth Analysis, By Application         

                                5.1.8 Market Attractiveness Analysis, By Application        

                                5.1.9 Market Share Analysis, By Application         

                5.2 Target                           

                                5.2.1 Introduction           

                                5.2.2 DNA polymerase  

                                5.2.3 NS3 Protease         

                                5.2.4 Reverse transcriptase        

                                5.2.5 Others      

                                5.2.6 Y-o-Y Growth Analysis, By Target   

                                5.2.7 Market Attractiveness Analysis, By Target

                                5.2.8 Market Share Analysis, By Target   

                5.3 End Users                    

                                5.3.1 Introduction           

                                5.3.2 Hospitals/Clinics   

                                5.3.3 Research Institutes             

                                5.3.4 Laboratory Centers             

                                5.3.5 Y-o-Y Growth Analysis, By End Users            

                                5.3.6 Market Attractiveness Analysis, By End Users          

                                5.3.7 Market Share Analysis, By End Users            

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Application

                                                6.1.3.3 By Target

                                                6.1.3.4 By End-Users

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Application

                                                6.1.4.3 By Target

                                                6.1.4.4 By End-Users

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Application

                                                6.1.5.3 By Target

                                                6.1.5.4 By End-Users

                6.2 Middle-East                                

                6.3 Africa                            

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Johnson & Johnson                 

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis International AG                     

                8.3 Roche Holding AG                   

                8.4 Pfizer                            

                8.5 Merck and Co. Inc                    

                8.6 GlaxoSmithKline plc                

                8.7 AstraZeneca AB                        

                8.8 Gilead Sciences                         

                8.9 Abbott Laboratories               

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Antiviral Drugs Market By Application, From 2019-2024 ( USD Billion )
  2. Middle East & Africa HIV/AIDS  Market By Region, From 2019-2024 ( USD Billion )
  3. Middle East & Africa Hepatitis Market By Region, From 2019-2024 ( USD Billion )
  4. Middle East & Africa Herpes Market By Region, From 2019-2024 ( USD Billion )
  5. Middle East & Africa Influenza Market By Region, From 2019-2024 ( USD Billion )
  6. Middle East & Africa Others Market By Region, From 2019-2024 ( USD Billion )
  7. Middle East & Africa Antiviral Drugs Market By Target, From 2019-2024 ( USD Billion )
  8. Middle East & Africa DNA polymerase Market By Region, From 2019-2024 ( USD Billion )
  9. Middle East & Africa NS3 Protease Market By Region, From 2019-2024 ( USD Billion )
  10. Middle East & Africa Reverse transcriptase Market By Region, From 2019-2024 ( USD Billion )
  11. Middle East & Africa Others Market By Region, From 2019-2024 ( USD Billion )
  12. Middle East & Africa Antiviral Drugs Market By End User, From 2019-2024 ( USD Billion )
  13. Middle East & Africa Hospitals/Clinics Market By Region, From 2019-2024 ( USD Billion )
  14. Middle East & Africa Research Institutes Market By Region, From 2019-2024 ( USD Billion )
  15. Middle East & Africa Laboratory Centers Market By Region, From 2019-2024 ( USD Billion )
  16. Middle East Antiviral Drugs Market By Application, From 2019-2024 ( USD Billion )
  17. Middle East Antiviral Drugs Market By Target, From 2019-2024 ( USD Billion )
  18. Middle East Antiviral Drugs Market By End User, From 2019-2024 ( USD Billion )
  19. Africa Antiviral Drugs Market By Application, From 2019-2024 ( USD Billion )
  20. Africa Antiviral Drugs Market By Target, From 2019-2024 ( USD Billion )
  21. Africa Antiviral Drugs Market By End User, From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample